EXECUTIVE ROUNDTABLE: Part 3; A great time for dealmaking in biotech

Executives from six US and EU biotechnology companies who spoke with Scrip Intelligence agreed that it's great to commercialize novel therapies without a partner and retain all financial rewards, but for any biotech firm that's looking for a deep-pocketed collaborator, now is a good time to be negotiating deals.